Literature DB >> 21614455

Can resistance to aspirin be reversed after an additional dose?

David Vivas1, Esther Bernardo, Juan Carlos García-Rubira, Luis Azcona, Ivan Núñez-Gil, Juan Jose González-Ferrer, Carlos Macaya, Dominick J Angiolillo, Antonio Fernández-Ortiz.   

Abstract

Aspirin resistance or aspirin non-responsiveness is a recently described phenomenon which has been consistently associated with an increased risk of cardiovascular events. This study was designed to determine the effects of an additional dose of 100 mg of aspirin on platelet function and proportion of aspirin non-responders using the platelet function analyzer-100 (PFA-100), in a well characterized population of stable coronary heart disease patients already on long-term aspirin treatment. Platelet function was assessed using PFA-100 in 141 patients (64.8 ± 10.1 years, 87.9% men) on long-term aspirin treatment (100 mg/day) before and 1 h after "in site" oral aspirin administration (100 mg). Prevalence of aspirin non-responders using PFA-100 was 50.7% (95% confidence interval 42.4-59). One hour after 100 mg of oral aspirin, reassessment of aspirin effects showed a prevalence of non-responders using PFA of 35.0% (95% CI 27.3-43.2) (P < 0.001 vs. pre-dose proportion). Using the PFA-100 system, reassessment of platelet function following oral administration of daily aspirin dosage significantly reduces the number of stable coronary disease patients considered to be non-responders to such treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21614455     DOI: 10.1007/s11239-011-0596-3

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  32 in total

Review 1.  Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review.

Authors:  Marcel M C Hovens; Jaapjan D Snoep; Jeroen C J Eikenboom; Johanna G van der Bom; Bart J A Mertens; Menno V Huisman
Journal:  Am Heart J       Date:  2007-02       Impact factor: 4.749

Review 2.  Aspirin resistance: truth or dare.

Authors:  Marie Lordkipanidzé; Chantal Pharand; Donald A Palisaitis; Jean G Diodati
Journal:  Pharmacol Ther       Date:  2006-08-17       Impact factor: 12.310

3.  Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.

Authors:  Andrew L Frelinger; YouFu Li; Matthew D Linden; Marc R Barnard; Marsha L Fox; Douglas J Christie; Mark I Furman; Alan D Michelson
Journal:  Circulation       Date:  2009-12-07       Impact factor: 29.690

4.  Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.

Authors:  Andrew O Maree; Ronan J Curtin; Michelle Dooley; Ronan M Conroy; Peter Crean; Dermot Cox; Desmond J Fitzgerald
Journal:  J Am Coll Cardiol       Date:  2005-10-04       Impact factor: 24.094

5.  Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?

Authors:  Rocio Gonzalez-Conejero; Jose Rivera; Javier Corral; Carmen Acuña; Jose A Guerrero; Vincente Vicente
Journal:  Stroke       Date:  2004-12-16       Impact factor: 7.914

6.  Effects of aspirin on platelet-neutrophil interactions. Role of nitric oxide and endothelin-1.

Authors:  A López-Farré; C Caramelo; A Esteban; M L Alberola; I Millás; M Montón; S Casado
Journal:  Circulation       Date:  1995-04-01       Impact factor: 29.690

7.  Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.

Authors:  Paul A Gurbel; Kevin P Bliden; Joseph DiChiara; Justin Newcomer; Willy Weng; Nagaraj K Neerchal; Tania Gesheff; Srivasavi K Chaganti; Amena Etherington; Udaya S Tantry
Journal:  Circulation       Date:  2007-06-11       Impact factor: 29.690

8.  A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.

Authors:  Marie Lordkipanidzé; Chantal Pharand; Erick Schampaert; Jacques Turgeon; Donald A Palisaitis; Jean G Diodati
Journal:  Eur Heart J       Date:  2007-06-14       Impact factor: 29.983

Review 9.  Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.

Authors:  J-L Reny; P De Moerloose; M Dauzat; P Fontana
Journal:  J Thromb Haemost       Date:  2008-01-10       Impact factor: 5.824

10.  Aspirin resistance and adverse clinical events in patients with coronary artery disease.

Authors:  Wai-Hong Chen; Xi Cheng; Pui-Yin Lee; William Ng; Jeanette Yat-Yin Kwok; Hung-Fat Tse; Chu-Pak Lau
Journal:  Am J Med       Date:  2007-07       Impact factor: 4.965

View more
  3 in total

1.  Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.

Authors:  Manling Xie; Zhilei Shan; Yan Zhang; Sijing Chen; Wei Yang; Wei Bao; Ying Rong; Xuefeng Yu; Frank B Hu; Liegang Liu
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

Review 2.  Prevalence rate of laboratory defined aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis.

Authors:  Parvin Ebrahimi; Zeynab Farhadi; Masoud Behzadifar; Hosein Shabaninejad; Hassan Abolghasem Gorji; Masood Taheri Mirghaed; Morteza Salemi; Kamyar Amin; Roghayeh Mohammadibakhsh; Nicloa Luigi Bragazzi; Rahim Sohrabi
Journal:  Caspian J Intern Med       Date:  2020

Review 3.  Mechanism of Improving Aspirin Resistance: Blood-Activating Herbs Combined With Aspirin in Treating Atherosclerotic Cardiovascular Diseases.

Authors:  Yixi Zhao; Shengjie Yang; Min Wu
Journal:  Front Pharmacol       Date:  2021-12-17       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.